Home>Topics>Companies>Novartis

Novartis NVS

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. Overpriced Expectations: Alcobra Will Get To Second Base, But No Home Run. Options Are Mispriced For An Unlikely Event

      Headlines

      Tue, 30 Sep 2014

      produce vital neurotransmitters in the brain. If MDX succeeds in reaching the market, Alcobra will compete amongst Novartis (NYSE: NVS ), Teva (NYSE: TEVA ), Shire (NASDAQ: SHPG ), Janssen and Lilly (NYSE: LLY ), currently marketing ADHD

    2. Novartis ordered to face U.S. lawsuit over doctor kickbacks

      Headlines

      Tue, 30 Sep 2014

      NEW YORK, Sept 30 (Reuters) - A federal judge said Novartis AG must face a U.S. government lawsuit accusing the Swiss drugmaker of paying multimillion-dollar kickbacks, including a $9,750 dinner for three at a Japanese restaurant, to induce doctors to prescribe its drugs.

    3. Johnson & Johnson Is The Most Attractive Mega-Cap Pharma Stock For Income Investors

      Headlines

      Tue, 30 Sep 2014

      are as follows: Johnson & Johnson (NYSE: JNJ ) Novartis AG (NYSE: NVS ) Pfizer (NYSE: PFE ) Merck & Co. (NYSE: MRK ..... device business and its consumer products segment. Novartis is a Swiss company that generated the Complete Story

    4. BRIEF-Cytos Biotechnology reports H1 revenue of 0.50 million Swiss francs

      Headlines

      Tue, 30 Sep 2014

      69 million Swiss francs as per June 30, 2014 * Says H1 revenue comprising deferred income from license fees paid by Novartis of 0.50 million Swiss francs, unchanged from H1 2013 * Says H1 net loss 23.4 million Swiss francs versus 13.6 million

    5. Phase 2 binimetinib data presented at ESMO

      Headlines

      Mon, 29 Sep 2014

      indication is for the treatment of NRAS-mutant melanoma. The regulatory filing is projected to be made in 2015. Binimetinib was invented by Array BioPharma ( ARRY -1.3% ) and licensed to Novartis ( NVS +0.6% ) in 2010. Post your comment!

    6. Cobimetinib Combo Results are Positive, but Melanoma Landscape Is Becoming More Challenging

      Commentary

      Mon, 29 Sep 2014

      conference and published in the New England Journal of Medicine. Given that the data were largely as expected and similar to Novartis ’ competing Mekinist and Tafinlar combination, which was recently acquired from GlaxoSmithKline and targets the same

    7. BRIEF- Novartis says Afinitor showed unprecedented survival in phase III trial

      Headlines

      Sat, 27 Sep 2014

      Sept 27 (Reuters) - Novartis AG : * Afinitor led to unprecedented median overall survival in phase III trial with

    8. Can Valeant's Glaucoma Drug Peak Sales Be Much Lower Than Claimed?

      Headlines

      Fri, 26 Sep 2014

      Mylan (NASDAQ: MYL ) is already selling a generic version. Another generic version of latanoprost is sold by Novartis (NYSE: NVS ) - it is made by the Alcon subsidiary. Complete Story »

    9. European Ad Comm supports Signifor label expansion

      Headlines

      Fri, 26 Sep 2014

      The EMA's CHMP adopts a positive opinion supporting the marketing approval of Novartis ' ( NVS -0.1% ) next-generation somatostatin analog (SSA) Signifor (pasireotide) long-acting release formulation for the treatment

    10. EU agency backs Novartis' Signifor drug

      Headlines

      Fri, 26 Sep 2014

      ZURICH, Sept 26 (Reuters) - A committee of the European Medicines Agency (EMA) has recommended Novartis drug Signifor LAR for European Union approval to treat a rare hormonal disorder, the Swiss drugmaker said on Friday.

    « Prev12345Next »
    Content Partners